Treatment of diverticular disease, targeting symptoms or underlying mechanisms

• Published in: Current opinion in pharmacology 2018-12, Vol.43, p.124-131
• Main Authors: Cuomo, Rosario, Cargiolli, Martina, Cassarano, Sara, Carabotti, Marilia, Annibale, Bruno
• Format: Article
• Language: English
• ISSN: 1471-4892; 1471-4973
• DOI: 10.1016/j.coph.2018.09.006

•There is no evidence supporting the use of drugs in asymptomatic diverticulosis for AD prevention.•Lower chronic GI symptoms have a multifactorial pathogenesis.•Fiber, probiotics, rifaximine and mesalazine are variously helpful in symptoms relief.•Systemic antibiotics can be avoided in uncomplicated diverticulitis.•No clear evidence-based treatment is available for secondary prevention of AD. Diverticular disease (DD) is a highly prevalent disease in western industrialized countries that encompasses a complex set of disorders. Because of its complexity and heterogeneity, both from a pathogenic and a clinical point of view, the management of this disease represent a challenge in clinical practice. This review aims to analyze and summarize the most recent evidence on the medical strategies for DD, considering separately the different stages of the disease, from prevention of diverticula formation to treatment of acute diverticulitis and prevention of recurrences. Based on some evidence, dietary fiber is useful to prevent diverticula formation and in diverticulosis, with no pharmacological treatment in these settings. Treatment of symptomatic uncomplicated diverticular disease as well as primary prevention of acute diverticulitis is based on probiotics, fibres, mesalazine and rifaximin, individually or as combination therapy, although a standard approach has not yet been defined. On the contrary, in acute diverticulitis (AD) recent acquisitions have clarified and standardized the role of systemic antibiotics, reserving its use only to complicated forms and in selected cases of uncomplicated disease. Secondary prevention of AD is essentially based on mesalazine and rifaximin but, despite promising results, no strong evidence have been produced. To date, grey areas remain in the medical management of DD.